FDA Grants Fast Track Designation to PTC518katie8288Sep 26, 20240 min readFDA Grants Fast Track Designation to PTC518 Huntington's Disease Program.pdfDownload PDF • 129KB
Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and other select markets
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Comments